Breaking News

MethylGene Makes Management Changes

March 15, 2013

Besterman, Baum and Gergen assume new roles

Jeffrey M. Besterman, Ph.D., has been appointed executive vice president of R&D and chief scientific officer at MethylGene, Inc. Joe Walewicz, vice president of business and corporate development, and Klaus B. Kepper, vice president finance and chief financial officer, will be leaving the company.
Dr. Charles Baum, chief executive officer, will take over Dr. Besterman’s responsibilities and Mark Gergen, chief operating officer has assumed the responsibilities of Mr. Kepper and Mr. Walewicz. 
"I want to personally thank Klaus, Jeff and Joe for their contributions to MethylGene," said Dr. Baum. “We wish them the best in their future pursuits.”
blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus